Asthma and COPD in cystic fibrosis intron-8 5T carriers. A population-based study

Table 4 Pulmonary status of 5T homozygotes and 5T/F508del compound heterozygotes sampled from the general population

Poly-T*	F508del heterozygosity	Age	Gender	Smoking status	FEV₁		Self-reported asthma^‡	Medication for asthma / bronchitis^¶	Hospitalization		Often bothered by
		years			%predicted	reversibility^†			asthma**	COPD**	dyspnoea	wheezing	phlegm
TG12-5T/TG12-5T		32	M	current smoker	92	-	yes	yes	no	no	yes	yes	no
TG11-5T/TG11-5T		62	F	current smoker	67	30%	no	no	no	no	no	no	no
TG11-5T	yes	33	F	current smoker	115	-	no	no	no	no	no	no	no
TG11-5T	yes	62	M	never smoker	121	-	no	no	no	no	no	no	no
TG12-5T	yes	65	F	ex-smoker	79	-	no	no	no	no	no	no	no
TG11-5T	yes	70	M	current smoker	128	-	no	no	no	no	no	no	no

*Number of TG repeats adjacent to the polythymidine tract included. ^†FEV₁ 30 minutes after inhalation of 0.5 mg terbutaline minus FEV₁ at 0 minutes divided by FEV₁ at 0 minutes times 100%; only individuals with FEV₁/FVC<0.7 were tested for FEV₁ reversibility. ^‡"Yes" to "Do you suffer from asthma?" ^¶"Yes" to "Do you daily take medication for asthma / bronchitis?" **Hospitalizations from asthma (ICD8: 493; ICD10: J45–46) and COPD (ICD8: 491–492; ICD10: J41–J44) were drawn from the Danish National Discharge Register from 1976 through 2000.